Reimbursement Achievable for Biologics in Psoriasis
September 1, 2003
The January FDA clearance of Biogen Inc.'s Amevive (alefacept) for the treatment of moderate-to-severe chronic plaque psoriasis officially ushered in the era of biologic treatments for dermatologists.
